HIGH SCHOOL EDITION
Journal of Student Research

Volume 13 Issue 2 (2024)

Gene-Based Therapy for Brain Cancer: Promises and Challenges

Anay Maheshwari

James B Conant High School, USA

ABSTRACT

Brain cancer, including gliomas and other malignant tumors, represents a devastating and challenging disease with limited treatment options and poor prognosis. Conventional therapies such as surgery, radiation, and chemotherapy have shown limited success, necessitating the exploration of alternative approaches. Gene-based therapy has emerged as a promising frontier in precision medicine, leveraging our growing understanding of the genetic and molecular drivers underlying brain tumor development and progression. This paper provides an overview of recent advancements in gene-based therapies for brain cancer, including gene editing techniques, gene silencing strategies, Immunotherapy, and more. Notably, these approaches aim to target specific oncogenes, tumor suppressor genes, and immune-related genes to inhibit tumor growth, induce apoptosis, and enhance the patient's immune response against cancer cells. Moreover, gene-based therapies offer the potential for personalized treatments tailored to individual patients based on their unique genetic profile, increasing treatment efficacy and minimizing adverse effects. While gene-based therapies have shown promising preclinical and early clinical results, challenges related to delivery, safety, and off-target effects remain to be addressed. This abstract emphasizes the urgent need for further research and large-scale clinical trials to establish the safety and long-term efficacy of gene-based therapies for brain cancer treatment. As the field continues to evolve, gene-based therapy holds great promise in reshaping the landscape of brain cancer management and providing hope for improved patient outcomes in the future.

Introduction

Cancer, a devastating and often fatal disease, poses significant challenges for conventional treatment approaches. Current therapies including surgery, radiation, and chemotherapy have shown limited success in combating the aggressive nature of brain tumors. Therefore, there is a pressing need for innovative and targeted therapeutic strategies to improve patient outcomes. Gene-based therapy, a cutting-edge treatment paradigm, is promising to revolutionize brain cancer treatment. This paper provides an overview of gene-based therapy's potential for curing brain cancer, exploring various approaches and their benefits. This introductory section aims to set the stage for an exploration of gene-based therapy's applications in the field of brain cancer treatment. This paper aims to examine the role of gene-based therapy in curing brain cancer and to dig into the various approaches currently being researched. In this paper, we will dive into the research of Gene Replacement Therapy, Gene Splicing Therapy, Immunotherapy, and more. The study of gene therapy has substantially progressed in recent years, with researchers harnessing its potential to target specific genetic mutations, enhance the immune system, inhibit tumor angiogenesis, and improve drug sensitivity. Understanding these innovative approaches is crucial to identifying the most effective and safe methods for tackling brain cancer. Although promising, gene-based therapy presents its own challenges, such as ensuring the safe delivery of therapeutic genes and providing a proper procedure in all hospitals. To sum up, gene-based therapy represents a ray of hope in the fight against brain cancer, offering a personalized and targeted approach to tackle this intimidating disease by analyzing the current state of research and the challenges ahead. This paper aims to shed light on the future prospects of gene-based therapy and emphasize the need for continuous research and advancements in this field.

Oncogene Silencing Therapy

One of the promising gene-based therapies for brain cancer is Oncogene Silencing Therapy, which aims to inhibit the activity of oncogenes that are crucial in promoting tumor growth and progression. Oncogenes are genes that have the potential to cause cancer when they are mutated or overexpressed. By selectively targeting and silencing these oncogenes, this therapeutic approach seeks to disrupt the molecular pathways that fuel tumor growth, ultimately curbing cancer progression.

A notable example of this therapy is the targeted inhibition of the epidermal growth factor receptor (EGFR), a common oncogene frequently found to be overactive in various brain tumors, including glioblastomas. EGFR regulates cell growth in normal cells, but when mutated, it can trigger uncontrolled cell proliferation and tumor formation. Oncogene silencing therapy aims to address this aberrant EGFR signaling in brain cancer. Several studies have shown promising results with EGFR-targeted gene silencing. Through the use of viral vectors, small interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs) are delivered to tumor cells, specifically targeting and degrading the EGFR messenger RNA (mRNA). This process effectively reduces the expression of the EGFR protein, leading to a decrease in tumor cell proliferation and increased cell death.



Figure 1. Cell division cycle.

Immunotherapy

Another hopeful therapy is Immunotherapy. Immunotherapy is using a person's own immune system to fight cancer by finding and attacking the cancer cells. This can be used by stimulating and boosting the natural defenses of your immune system to find and attack the cells. The immune system looks to eliminate all dangerous cells in your body to prevent diseases. Obviously, this doesn't work perfectly because even healthy immune systems can still have cancerous cells. Some of the reasons for this are that your immune system doesn't see the difference between foreign cancerous cells and healthy ones and when they do the response may not be strong enough to kill all the cells. Immunotherapy, however, aims to eliminate all these issues by helping recognize these and strengthening the immune system's response to them. Specifically, Immunotherapy consists of Checkpoint Inhibitors, Cancer Vaccines, Monoclonal antibodies, Cytokines, and Oncolytic viruses. Checkpoint Inhibitors are the brain's ability to detect foreign cells which can be cancerous. Having the brain detect these cells will allow the immune system to kill the cancerous cells. Cancer Vaccines help prevent the spread of cancer through viruses. This is an extremely effective way to prevent cancer as 45 percent of all brain cancers come from viruses. This would eliminate all of those forms. Monoclonal antibodies design antibodies that specifically target one part of a certain antigen. Several studies have shown the success of these antibodies when used effectively, however, finding the right is not easy. The future of Monoclonal antibodies is extremely bright and more research is dire in treating brain cancer. Cytokines are a treatment that uses small proteins to stimulate the immune cells to attack cancer. This is especially important in your own immune system which can be easily manipulated into killing all the cancerous cells. Finally, Oncolytic viruses. This treatment uses viruses that have been modified in a lab to infect and kill certain tumor cells. These viruses can be optimized to your own genes to kill cancer cells.



Figure 2. Immunotherapy finding the cancernregions and using the immune system to attack it.

Gene Therapy Replacement

Gene therapy has emerged as a promising approach for treating brain cancer, offering potential solutions to the limitations of conventional therapies. Brain cancer, particularly glioblastoma, is an aggressive and lethal disease with limited treatment options. Gene therapy replacement, which involves the introduction of functional genes into cancerous cells to correct or replace defective genes, has shown encouraging results in preclinical studies and early-phase clinical trials. The primary objective of gene therapy in brain cancer is to inhibit tumor growth, induce apoptosis in cancer cells, and enhance the overall efficacy of treatment while minimizing damage to healthy brain tissue. By targeting specific genetic abnormalities that contribute to tumor progression, gene therapy holds the potential to revolutionize the treatment landscape for brain cancer patients, offering new hope for improved outcomes and extended survival rates. However, despite the promises it holds, gene therapy is not without challenges, as the complexity of the brain's structure and the presence of the blood-brain barrier present significant obstacles that must be overcome to ensure safe and effective gene delivery. As research progresses, addressing these hurdles will be crucial in unlocking the full potential of gene therapy replacement as a transformative and personalized approach to combating brain cancer. To dive in, Gene therapy Replacement treatments comprise Plasmid DNA, Viral Vectors, Bacterial Vectors, Human Gene Editing technology, and Patient-derived cellular gene therapy products.

Plasmid DNA

Plasmid DNA has emerged as a promising vector for gene therapy in treating brain cancer due to its unique properties and potential therapeutic benefits. Plasmids are small, circular DNA molecules that can be engineered to carry specific therapeutic genes and regulatory elements. When used in gene therapy for brain cancer, plasmids can be introduced into cancerous cells to deliver therapeutic genes that either suppress tumor growth, induce apoptosis, or enhance the immune response against cancer cells. One of the significant advantages of using plasmid DNA is its ability to be easily manipulated in the laboratory, allowing for the customization of therapeutic payloads based on the genetic profile of an individual patient's tumors. Furthermore, plasmid-based gene therapy offers a safer alternative to viral vectors, as it reduces the risk of immune responses and potential toxicity associated with viral delivery systems. However, challenges remain in achieving efficient and targeted delivery of plasmid DNA to brain tumor cells, primarily due to the blood-brain barrier's restrictive nature. Nevertheless, ongoing research and advancements in nanotechnology and non-viral delivery methods hold promise in overcoming these obstacles, making plasmid DNA a hopeful avenue for the development of innovative and effective treatments for brain cancer.



Figure 3. Illustration of Plasmid entering bacterium and replicating DNA.

Viral Vectors

Viral vectors have sprung up as a powerful tool in the field of gene therapy for treating brain cancer, offering an efficient and targeted delivery system for therapeutic genes. These vectors are modified viruses that have had their disease-causing genes removed and replaced with therapeutic genes. By leveraging the natural ability of viruses to infect cells, viral vectors can effectively deliver therapeutic genes directly into brain tumor cells, allowing for precise targeting and minimizing damage to healthy brain tissue. This approach holds the potential to address the challenges posed by the blood-brain barrier, which restricts the passage of many therapeutic agents into the brain. Viral vectors can be engineered to carry a wide range of therapeutic payloads, including genes that inhibit tumor growth, promote apoptosis in cancer cells, or activate the immune system to target and destroy cancerous cells. Despite their promising potential, the use of viral vectors in brain cancer gene therapy also presents some challenges, such as immune responses against the viral components and potential toxicity concerns. Ongoing research is focused on optimizing the safety and efficacy of viral vectors, with advancements in vector design and delivery techniques paving the way for their successful integration into targeted and personalized treatments for brain cancer patients. The future of Viral Vectors is heavily dependent on the safety and continued growth of research for the procedure.

Bacterial Vectors

Bacterial vectors have shown promising potential in revolutionizing the treatment of brain cancer. These vectors are genetically engineered bacteria that possess the ability to target and selectively infiltrate tumor cells in the brain. By exploiting the unique environment of the brain tumors, bacterial vectors can deliver therapeutic payloads directly to the affected areas, bypassing the blood-brain barrier that often hinders the delivery of conventional treatments. One of the most significant advantages of bacterial vectors is their ability to trigger an immune response, which aids in the destruction of cancer cells and activates the body's natural defense mechanisms against the tumor. Moreover, these vectors can be further modified to carry specific anti-cancer agents, such as toxins or gene-editing tools, enhancing their efficacy in eradicating cancer cells. Though still in its early stages of research, the use of bacterial vectors in brain cancer treatment holds great promise for improved patient outcomes and may offer a novel and targeted approach to combat this devastating disease.

Human Gene Editing Technology

Human gene editing technology is the simple concept of disrupting harmful genes and repairing them. Strands of mutated DNA can create cancer in your brain. To combat this, Human gene editing technology can cut a DNA sequence at a specific genetic location and delete DNA sequences which can change the strand of the harmful gene. However, this does pose some downsides. Genetically modified (GM) animals and plants are well-known for their ability to adapt to different environments better than regular ones. There are concerns about the possibility of uncontrollable growth, turning the species into invasive ones, to an extent where they harm the environment and the organisms themselves.



Figure 4.-Cancer cell turns healthy after blocking gene blocks faulty gene.

Gene Therapy Slicing

Gene therapy slicing, also known as gen editing, has emerged as a groundbreaking approach in the battle against brain cancer. This innovative technique involves the precise modification of the cancer cells' genetic material to target and disrupt specific genes responsible for tumor growth and proliferation. By utilizing gene-editing tools like CRISPR-Cas9, researchers can deactivate oncogenes or activate tumor-suppressor genes, thereby curbing the uncontrolled growth of cancerous cells. Gene slicing offers the potential to develop highly personalized and targeted treatments tailored to the genetic makeup of each patient's brain tumor. This level of customization can lead to more effective outcomes and reduced side effects compared to conventional therapies. However, gene therapy slicing for brain cancer is still in its early stages and faces challenges, such as delivery to the brain and off-target effects. Despite these obstacles, this technology holds immense promise and could eventually lead to transformative advancements in the treatment of brain cancer, offering hope to patients and their families for a brighter future. Gene Slicing aims to target cancer-causing genes, enhance the immune system and repair mutated genes. Scientists can use gene editing to target and disable specific genes that promote cancer growth. By disrupting these genes, the cancer cell's ability to proliferate may be reduced, thus slowing down the progression of the disease. Gene editing can also be used to modify immune cells like T cells, making them better at recognizing and attacking cancer cells in the brain. This approach is known as CAR-T cell therapy, and it has shown promising results in treating certain types of blood cancers. In some cases, brain cancer is caused by mutations in specific genes. Gene editing technologies could potentially correct these mutations, restoring the normal function of the affected genes and potentially stopping or reversing cancer growth.

CAR-T

To dive in, CAR-T is an innovative treatment that involves genetically modifying a patient's own T cells to express chimeric antigen receptors (CARs) that can recognize and target specific antigens on the surface of brain cancer cells. Once infused back into the patient, these engineered CAR-T cells can selectively seek out and attack the tumor cells while sparing healthy brain tissue. CAR-T cell therapy offers a highly targeted and personalized approach to combat brain cancer, especially in cases where traditional treatments have limited effectiveness. Though challenges remain, such as the need for improved delivery across the blood-brain barrier, ongoing research and clinical trials are making significant strides in optimizing CAR-T cell therapy's safety and efficacy, raising hopes for a more effective and potentially curative treatment option for patients with brain cancer.

Suicide Gene Therapy

Suicide gene therapy holds great promise as a potential treatment for brain cancer. In this approach, therapeutic genes are introduced into cancer cells, making them susceptible to a non-toxic prodrug. Once the prodrug is administered, the therapeutic genes within the cancer cells convert it into a toxic substance, leading to the death of these specific cells while sparing healthy surrounding tissue. Suicide gene therapy offers the advantage of targeted treatment, reducing the risk of collateral damage to normal brain cells. Additionally, it can be used in combination with other treatments, such as surgery or radiation therapy, to enhance their effectiveness. Although challenges exist in optimizing the delivery and efficacy of this therapy, ongoing research and preclinical studies show promising results, fueling hope that suicide gene therapy could become a valuable addition to the arsenal of brain cancer treatment options in the future. In conclusion, gene therapy has shown great promise in revolutionizing the approach to brain cancer. The significant advances in our understanding of the genetic basis of brain tumors and the development of innovative therapeutic techniques have opened new avenues for targeted and personalized treatments. By targeting specific genetic alterations responsible for tumor growth and progression, gene therapy holds the potential to enhance the efficacy and specificity of treatments while minimizing the adverse effects on healthy tissues. While challenges and complexities remain, ongoing research and clinical trials continue to shed light on the potential benefits of gene therapy for brain cancer patients. Immunotherapy, Gene editing, Human gene editing technology, and even more gene therapy treatments are the future of treating brain cancer. As this field continues to evolve, it is vital to ensure rigorous testing, ethical considerations, and comprehensive safety assessments to ultimately translate these.

Method How they work? Future research	Method How they work? Future research	Method How they work? Future research
Immunotherapy	Recombinant cancer vaccines: Trains immune system to recognize cancer cells by presenting it highly antigenic and immunostimulatory cellular debris.	Vaccines need to be person specific and many hospitals don't have facilities to create them. Generic solution that combine multiple genes may allow for mass production.
	Delivers immunostimulatory genes, mainly cytokines to the tumor and encourage development of antitumor antibodies.	Gene therapy is still only able to generate modest response, Hence the person is requiring Chemotherapy. More advancement that ensures that Chemotherapy is not needed will help accelerate adoption.
	Tumor antigens is added to a certain cell type. This causes immune reaction killing the cancer cells.	More work on how to use for Breast and Prostrate cancer can be promising. However, results to date are not very helpful.
Oncogene silencing therapy.	Infect cancer cells and induce cell death through the propagation of the virus, expression of cytotoxic proteins and cell lysis.	Improve treatment vector and the production rate for viral particles so that they outstrip growth rate of the uninfected cancer cells
		Ensure that surrounding cells are not impacted.

Figure 5: Future research opportunity for select Gene Therapy

Acknowledgments

I would like to thank my advisor for the valuable insight provided to me on this topic.

References

1. American Gene Technologies. (n.d.). The Future of Gene Therapy. Retrieved from https://www.americangene.com/blog/the-future-of-gene-therapy/#:~:text=Gene%20therapy's%20advantage%20is%20its,cost%20of%20recently%20approved%20therapies.

2. Hemgenix. (n.d.). How It Works. Retrieved from https://www.hemgenix.com/about-hemgenix/how-it-works#:~:text=HEMGENIX%20uses%20a%20gene%20therapy,support%20natural%20blood%2Dclotting%20ability.

3. https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/splicing#:~:text=The%20process%20by%20which%20introns,synthesis%20of%20a%20specific%20protein.

4. National Center for Biotechnology Information. (2009). Title of the article. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778045/

5. American Cancer Society. (n.d.). Immunotherapy. Retrieved from https://www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy.html#:~:text=Immunotherapy%20is%20treatment%20that%20uses,find%20and%20attack%20cancer%20cells.

6. U.S. Food and Drug Administration. (n.d.). What Is Gene Therapy? Retrieved from https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/what-gene-therapy#:~:text=Gene%20therapy%20is%20a%20technique,that%20is%20not%20functioning%20properly.